# A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

> **NCT02173249** · PHASE1 · COMPLETED · sponsor: **Aciex Therapeutics, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AC 170 0.24%

## Key facts

- **NCT ID:** NCT02173249
- **Lead sponsor:** Aciex Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173249, "A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02173249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*